New hope for psoriasis patients who Didn't respond to leading therapies
NCT ID NCT06336343
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a drug called bimekizumab in 60 adults with moderate-to-severe plaque psoriasis who had not improved with other similar treatments. The drug works by blocking certain inflammatory substances in the body to reduce skin redness, scaling, and thickness. The main goal was to see if it could clear most of the psoriasis, with less than 1% of the body affected.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLAQUE PSORIASIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Icahn School of Medicine at Mount Sinai
New York, New York, 10029, United States
-
Windsor Dermatology - Psoriasis Treatment Center of Central New Jersey
East Windsor, New Jersey, 08520, United States